Computational Modeling Predicts Immuno-Mechanical Mechanisms of Maladaptive Aortic Remodeling in Hypertension

Marcos Latorre1, Matthew R Bersi2, Jay D Humphrey1,3

  • 1Department of Biomedical Engineering Yale University, New Haven, CT, USA.

International Journal of Engineering Science
|August 25, 2020
PubMed

Insights

Hypertension causes aortic stiffening through inflammation-driven fibrosis. Controlling inflammation is key to preventing maladaptive changes in the aorta, but preserving matrix degradation is crucial for mechanical health.

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Physiology
  • Computational Biology

Background:

  • Uncontrolled hypertension is a significant risk factor for cardiovascular diseases.
  • Hypertension increases central artery stiffness, a key indicator and initiator of cardiovascular disease.
  • The precise biochemomechanical mechanisms linking hypertension to aortic stiffening are not fully understood.

Purpose of the Study:

  • To develop and utilize a novel computational model of aortic growth and remodeling.
  • To investigate the differential effects of induced hypertension on thoracic and abdominal aortas in a mouse model.
  • To elucidate constituent-level mechanisms driving aortic stiffening under hypertension.

Main Methods:

  • Development of a computational model treating the aortic wall as a constrained mixture of constituents.
  • Simulation of aortic growth and remodeling in response to induced hypertension in a mouse model.
  • Analysis of how material properties and turnover rates of aortic wall constituents contribute to stiffening.

Main Results:

  • The model successfully captured differential hypertensive effects on thoracic and abdominal aortas.
  • Aorta demonstrated local mechano-adaptation to elevated blood pressure without significant inflammation.
  • Marked inflammation promoted maladaptive adventitial fibrosis via increased collagen deposition without compensatory matrix degradation.

Conclusions:

  • Local mechano-adaptation is possible in the aorta under hypertension.
  • Inflammation drives maladaptive aortic fibrosis, primarily in the adventitia.
  • Therapeutic strategies should target inflammation to reduce fibrosis while preserving matrix degradation for mechanical homeostasis.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
549
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
759